These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 24681270

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [Abstract] [Full Text] [Related]

  • 23. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 24. [Effectiveness of Broncho-Vaxom in prevention of recurrent upper respiratory tract infection in children].
    Zielnik-Jurkiewicz B, Jurkiewicz D, Stankiewicz W.
    Pol Merkur Lekarski; 2005 Nov; 19(113):625-9. PubMed ID: 16498798
    [Abstract] [Full Text] [Related]

  • 25. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D, La Fauci V, Squeri R, Cannavò G, Bacilieri S, Panatto D, Gasparini R, Amicizia D.
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
    Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S.
    Vaccine; 2012 Jan 20; 30(5):936-40. PubMed ID: 22138210
    [Abstract] [Full Text] [Related]

  • 27. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 20; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 28. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.
    Vaccine; 2011 Feb 24; 29(10):1921-8. PubMed ID: 21219987
    [Abstract] [Full Text] [Related]

  • 29. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC, Kung HC, Kao TM, Wu H, Dong SX, Hu MH, Chou AH, Chong P, Hsieh SM, Chang SC.
    J Microbiol Immunol Infect; 2013 Dec 24; 46(6):448-55. PubMed ID: 23022464
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
    Shim DH, Ko HJ, Volker G, Potter AA, Mutwiri G, Babiuk LA, Kweon MN.
    Vaccine; 2010 Mar 08; 28(11):2311-7. PubMed ID: 20060944
    [Abstract] [Full Text] [Related]

  • 31. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 32. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, Yang J, Adderson EE, McCullers JA, Flynn PM.
    J Infect Dis; 2011 Nov 15; 204(10):1475-82. PubMed ID: 21949042
    [Abstract] [Full Text] [Related]

  • 33. Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. A randomized, double-blind clinical trial.
    Tricarico D, Varricchio A, D'Ambrosio S, Ascione E, Motta G.
    Arzneimittelforschung; 2004 Nov 15; 54(1):57-63. PubMed ID: 14979610
    [Abstract] [Full Text] [Related]

  • 34. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.
    Vaccine; 2011 Nov 15; 29(49):9209-13. PubMed ID: 21974995
    [Abstract] [Full Text] [Related]

  • 35. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.
    Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W.
    Vaccine; 2012 Jun 29; 30(31):4655-60. PubMed ID: 22575166
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
    Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, Sékaly RP, Boivin G.
    Vaccine; 2011 Feb 04; 29(7):1359-63. PubMed ID: 21185423
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.